CDK2i Program (Type6 Therapeutics)

N/A

Report date: 2026/01/07 10:16:09
NMEFirst In Class

Base Information

Drug NameCDK2i Program (Type6 Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesType6 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesType6 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A